Cargando…

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized, Open-Label Trial

BACKGROUND: Antibody responses to non–egg-based standard-dose cell-culture influenza vaccine (containing 15 µg hemagglutinin [HA]/component) and recombinant vaccine (containing 45 µg HA/component) during consecutive seasons have not been studied in the United States. METHODS: In a randomized trial o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaglani, Manjusha, Kim, Sara S, Naleway, Allison L, Levine, Min Z, Edwards, Laura, Murthy, Kempapura, Dunnigan, Kayan, Zunie, Tnelda, Groom, Holly, Ball, Sarah, Jeddy, Zuha, Hunt, Danielle, Wesley, Meredith G, Sambhara, Suryaprakash, Gangappa, Shivaprakash, Grant, Lauren, Cao, Weiping, Gross, F Liaini, Mishina, Margarita, Fry, Alicia M, Thompson, Mark G, Dawood, Fatimah S, Flannery, Brendan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907492/ https://www.ncbi.nlm.nih.gov/pubmed/36031405 http://dx.doi.org/10.1093/cid/ciac683

Ejemplares similares

Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020
por: Naleway, Allison L, et al.
Publicado: (2023)

Consistency of self‐reported and documented historical influenza vaccination status of US healthcare workers
por: Regan, Annette K., et al.
Publicado: (2022)

Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet™ or in vivo-jetPEI(®) induces enhanced serological, cellular and protective immune responses
por: Cao, Weiping, et al.
Publicado: (2018)

Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017
por: Gaglani, Manjusha, et al.
Publicado: (2020)

A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose
por: Sayedahmed, Ekramy E., et al.
Publicado: (2018)

COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers
por: Lutrick, Karen, et al.
Publicado: (2022)

Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses
por: Hassan, Ahmed O., et al.
Publicado: (2017)

Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice
por: Cao, Weiping, et al.
Publicado: (2017)

Immunosenescence and Influenza Vaccine Efficacy
por: Sambhara, Suryaprakash, et al.
Publicado: (2009)

Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand
por: Kittikraisak, Wanitchaya, et al.
Publicado: (2016)

Influenza virus exploits tunneling nanotubes for cell-to-cell spread
por: Kumar, Amrita, et al.
Publicado: (2017)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

2760. Accounting for Vaccination History in Estimates of Current Season Vaccine Effectiveness in the US Flu VE Network, 2012–2013 Through 2017–2018
por: Kim, Sara S, et al.
Publicado: (2019)

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
por: Sayedahmed, Ekramy E., et al.
Publicado: (2020)

Interim Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness — United States, February 2020
por: Dawood, Fatimah S., et al.
Publicado: (2020)

Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
por: Yoon, Sarang K., et al.
Publicado: (2022)

Challenges for vaccination in the elderly
por: Aspinall, Richard, et al.
Publicado: (2007)

Influenza Vaccine Effectiveness in the United States During the 2016–2017 Season
por: Flannery, Brendan, et al.
Publicado: (2017)

A Dual-Functioning 5ʹ-PPP-NS1shRNA that Activates a RIG-I Antiviral Pathway and Suppresses Influenza NS1
por: Singh, Neetu, et al.
Publicado: (2020)

Differences between Frequentist and Bayesian inference in routine surveillance for influenza vaccine effectiveness: a test-negative case-control study
por: Jackson, Michael L., et al.
Publicado: (2021)

Progress towards the Development of a Universal Influenza Vaccine
por: Wang, Wen-Chien, et al.
Publicado: (2022)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021
por: Thompson, Mark G., et al.
Publicado: (2021)

No safety signals for GSK quadrivalent influenza vaccine
Publicado: (2022)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
por: Li, Athena P. Y., et al.
Publicado: (2021)

Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections
por: Elkashif, Ahmed, et al.
Publicado: (2021)

Influenza Virus Infects and Depletes Activated Adaptive Immune Responders
por: Bohannon, Caitlin D., et al.
Publicado: (2021)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
por: Kosen, Soewarta, et al.
Publicado: (2017)

Ongoing inadequacy of quadrivalent HPV vaccine safety studies
por: Little, Deirdre T, et al.
Publicado: (2020)

Quadrivalent influenza nanoparticle vaccines induce broad protection
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2021)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Influenza Vaccine Effectiveness among Elderly and Non-Elderly Adults Aged ≥45 Years in the United States, 2011–2012 to 2015–2016
por: Havers, Fiona P, et al.
Publicado: (2017)

Detection and Stability of SARS-CoV-2 in Three Self-Collected Specimen Types: Flocked Midturbinate Swab (MTS) in Viral Transport Media, Foam MTS, and Saliva
por: Veguilla, Vic, et al.
Publicado: (2022)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o292e72ligblt60i1csc63hvpm